Condition: Extensive-stage Small-cell Lung Cancer · Sponsor: Jazz Pharmaceuticals
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
This description comes directly from the study's public registry record.
Clinical Trial Disclosure & Transparency · 215-832-3750 · ClinicalTrialDisclosure@JazzPharma.com
Always discuss trial participation with your own doctor first.
| Valkyrie Clinical Trials, Inc. | Los Angeles, California, United States | Recruiting |
| Cancer Specialists of North Florida | Jacksonville, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Carolina Blood and Cancer Care | Rock Hill, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07459634